Many of the posts that I have written discussed the need for evaluating our current advanced prostate cancer drugs in both combinations and their sequencing. We have a number of new drugs, but we don’t understand how best to sequence them, or whether or not some drugs would do better and extend life by taking [...]
Men with metastatic castrate resistant prostate cancer (mCRPC) have become fortunate over the last few years as there we now have a number of new drugs available which can extend our life and can also have some palliative effects. However, as we have more treatments being approved, we find that we are faced with a [...]
Somehow I have been negligent and not let people know that I have written and posted a major update of my “Guide to Advanced Prostate Cancer.” As in the past, it is available as a free download from the Malecare web site. Helping me to update the book was prostate cancer survivor Craig Pynn and [...]
Abiraterone acetate (AA) or Zytiga has demonstrated a survival benefit in the pre-chemotherapy setting for men with advanced prostate cancer that has become castrate resistant (mCRPC). As a result it is in widespread clinical use in the United States prior to the use of chemotherapy with docetaxel. Since its FDA approval post chemotherapy there has [...]
The FDA approved Abiraterone acetate (Zytiga) plus prednisone because it demonstrated a survival benefit for men with metastatic castrate resistant prostate cancer (mCRPC) in the pre-chemotherapy setting. Given the newness of the approval of Zytiga in this disease stage there is a lack of data on how Zytiga affects the efficacy of enzalutamide (Xtandi) or [...]